Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering.

Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating lymphocytes (TILs) have greatly improved outcomes for patients with advanced cancers, particularly metastatic melanoma. The approval o…

Preview only. Read the full abstract at the source